Pharma News

Revenue for Rabies vaccine is expected to have a CAGR of 1.43% through 2038

Rabies vaccine is a Inactivated Vaccine owned by Bavarian Nordic, and is involved in 1 clinical trial, which is planned.

Rabies vaccine is an adsorbed virus vaccine which acts by inducing an active immune response to promote immunity. Rabies without actually causing the disease works by provoking the bodies immune response to this virus. When the body is exposed to foreign organisms such as bacteria and viruses, the immune system produces antibodies against them. These antibodies help the body to recognize and kill the foreign organisms. Thus these antibodies remain in the body to help protect the body against future infections with the same organism, which is known as active immunity

The revenue for Rabies vaccine is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rabies vaccine NPV Report.

Rabies vaccine is currently owned by Bavarian Nordic.

Rabies vaccine Overview

Rabies vaccine (Rabipur/ RabAvert/ Rasilvax/ Rabipor/ Rabivac) is a egg based highly immunogenic preparation, produced on purified chick embryo cells (PCEC). It is formulated as injectable powder for solution, powder for suspension or solution for intramuscular route of administration. Rabies vaccine is indicated to stimulate the body, for production of anti-rabies virus immunity and for the prevention of rabies of all age groups.

Bavarian Nordic Overview

Bavarian Nordic is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, respiratory syncytial virus, COVID-19, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.

The company reported revenues of (Danish Krone) DKK1,897.9 million for the fiscal year ended December 2021 (FY2021), an increase of 2.5% over FY2020. The operating loss of the company was DKK313.6 million in FY2021, compared to an operating profit of DKK379.6 million in FY2020. The net loss of the company was DKK464.8 million in FY2021, compared to a net profit of DKK277.5 million in FY2020.
The company reported revenues of DKK1,003.6 million for the third quarter ended September 2022, an increase of 87% over the previous quarter.

Quick View – Rabies vaccine

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
Key Companies
Highest Development Stage

Source link
#Revenue #Rabies #vaccine #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *